On November 17, 2025, Nuvalent, Inc. announced encouraging results from its clinical trial of neladalkib, a treatment for advanced ALK-positive non-small cell lung cancer, showing a 31% objective response rate among TKI pre-treated patients and an 86% response rate among TKI-naïve patients. The filing confirms ongoing enrollment and future discussions with the FDA regarding the treatment's next steps.